Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid Leukemia

Phase 1 Completed 65 enrolled AstraZeneca

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess safety and tolerability of multiple ascending doses of AZD1152 and to assess effect of AZD1152 on the rate of complete remission in patients with relapsed acute myeloid leukaemia.

Timeline

Start: 2006-05
Primary completion: 2009-10
Completion: 2010-04

Publications

Lowenberg B, Muus P, Ossenkoppele G, Rousselot P, Cahn JY, Ifrah N, Martinelli G, Amadori S, Berman E, Sonneveld P, Jongen-Lavrencic M, Rigaudeau S, Stockman P, Goudie A, Faderl S, Jabbour E, Kantarjian H. Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. Blood. 2011 Dec 1;118(23):6030-6. doi: 10.1182/blood-2011-07-366930. Epub 2011 Oct 5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	barasertib	Small molecule	50 mg	Other
Subject	barasertib	Small molecule	100 mg	Other
Subject	barasertib	Small molecule	200 mg	Other
Subject	barasertib	Small molecule	400 mg	Other
Subject	barasertib	Small molecule	800 mg	Other
Subject	barasertib	Small molecule	1200 mg	Other
Subject	barasertib	Small molecule	1600 mg	Other

Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid Leukemia

Summary

Timeline

Publications

Drugs

Indications